a clinical-stage biopharmaceutical company, which engages in the development of therapeutics for the treatment of Pediatric Growth Hormone Deficiency (PGHD)
Industry Biotechnology
A.I.dvisor tells us that LUMO and MOR have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LUMO and MOR's prices will move in lockstep.
Ticker / NAME | Correlation To LUMO | 1D Price Change % | ||
---|---|---|---|---|
LUMO | 100% | -1.91% | ||
MOR - LUMO | 27% Poorly correlated | -0.22% | ||
NUVL - LUMO | 27% Poorly correlated | -0.44% | ||
BNOX - LUMO | 26% Poorly correlated | -3.64% | ||
SLS - LUMO | 25% Poorly correlated | -1.68% | ||
SYBX - LUMO | 25% Poorly correlated | -1.75% | ||
More |